NCT00790101终止4 期
An 18-Month, Multicenter, Parallel-Group Study to Determine The Relative Efficacy of Risedronate Versus Raloxifene in Subjects Who Have Discontinued Hormone Replacement Therapy (HRT) for Early Intervention in Osteoporosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- Sanofi
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Compare the effects of risedronate and raloxifene on lumbar spine (LS) bone mineral density (BMD) in osteopenic women previously treated with HRT, who discontinued HRT at least 3 months prior to the study but no greater than 18 mos
研究概览
简要总结
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- — 至 65 Years（Child, Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal, ambulatory females, "postmenopausal" defined as the absence of menses for at least 12 continuous months)
- •In general good health as determined by medical history, physical examination, and laboratory tests
- •LS spine BMD T-score between -1.0 and -2.4, inclusive
- •At least one analyzable BMD site at both the hip (left or right) and LS spine (at least 3 measurable lumbar spine vertebrae, without fracture or sufficient degenerative disease)
- •Currently receiving no medications for the treatment or prevention of osteoporosis
- •Had been on continuous HRT for at least 1 year prior to enrollment. The HRT must have ended within 18 months prior to the baseline visit, and the subject must have been off HRT medication for at least 3 months at the time of baseline visit
- •Subjects rendered menopausal by surgical procedures between the ages of 55 and 65 years
排除标准
- •A history of cancer within 10 years prior to entry into the study, except for relatively "benign" and cured skin cancers such as basal and squamous cell carcinoma
- •A history of hyperparathyroidism, hyperthyroidism, osteomalacia, or other metabolic bone disease within one year prior to enrollment
- •Any condition or disease that may interfere with the evaluation of at least 3 lumbar vertebrae (not necessarily contiguous), determined in a screening radiograph by a radiologist at the central facility (e.g., confluent aortic calcifications, severe osteoarthritis, spinal fusion, lumbar spine fractures)
- •Evidence of clinically significant organic or psychiatric disease on history or physical examination, which in the opinion of the investigator would prevent the patient from completing the study
- •Markedly abnormal pretreatment laboratory finds that, in the opinion of the investigator, would prevent the patient from completing the study
- •A history of using any of the following medications prior to starting study:
- •Any bisphosphonate therapy
- •Selective estrogen receptor modulators (SERMs)
- •Parathyroid hormone
- •Fluorides
- •Calcitonin
- •Calcitriol (>1.5 mcg/week)
- •Corticosteroids on a chronic basis for period equal to or greater then 3 months
- •Received a depot injection of >10,000 IU Vitamin D in the past 12 months
- •A history of recurrent nephrolithiasis or a history of one episode of nephrolithiasis within 1 year of study entry
- •Serum creatinine >1.6 mg/dl
- •Unable to sit or stand upright for 30 minutes after taking the morning dose of risedronate
- •A history of deep vein thrombosis or other coagulation disorders
- •Severe hepatic insufficiency
- •A history of hypersensitivity to raloxifene, risedronate, or to drugs with similar chemical structures
- •Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
- •Subjects found to have one or more vertebral fractures after completing thoracic and LS spine films
- •Subjects who have experienced a low impact fracture related to osteopenia within two years of baseline visit
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
研究组 & 干预措施
1
Experimental
Risedronate 35mg once a week
干预措施: Risedronate (Drug)
2
Active Comparator
Raloxifene 60mg daily
干预措施: Raloxifene (Drug)
3
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Compare the effects of risedronate and raloxifene on lumbar spine (LS) bone mineral density (BMD) in osteopenic women previously treated with HRT, who discontinued HRT at least 3 months prior to the study but no greater than 18 mos
次要结局
- Compare the effects of risedronate, raloxifene, and placebo on BMD of the hip
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).CoronavirusHypoxic Respiratory FailureHypoxemic Respiratory FailureRespiratory ComplicationRespiratory InsufficiencyCardiac DysfunctionPulmonary InflammationCytokine StormCOVID 19SARS-CoV-2PneumoniaCardiac EventCardiac ComplicationCardiac FailureCardiac InfarctRespiratory FailureAcute Respiratory Distress SyndromePulmonary EdemaNCT04433546PhaseBio Pharmaceuticals Inc.54
已完成
3 期
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With AsthmaAsthmaNCT03769090Bond Avillion 2 Development LP3,132
已完成
3 期
Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.Hormone Replacement TherapyNCT01070979Warner Chilcott249
已完成
3 期
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With AsthmaAsthmaNCT03847896Bond Avillion 2 Development LP1,001
已完成
3 期
Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder PatientsBipolar DisorderManiaNCT00448578AstraZeneca150